上海市锦天城（深圳）律师事务所 法律意见书 上海市锦天城（深圳）律师事务所 关于深圳市卫光生物制品股份有限公司 2023 年度股东大会的 法律意见书 地址：深圳市福田中心区福华三路卓越世纪中心 1 号楼 21-23 层 电话：0755-82816698 传真：0755-82816898 上海市锦天城（深圳）律师事务所 法律意见书 上海市锦天城（深圳）律师事务所 关于深圳市卫光生物制品股份有限公司 2023 年度股东大会的 法律意见书 致：深圳市卫光生物制品股份有限公司 上海市锦天城（深圳）律师事务所（以下简称"本所"）接受深圳市卫光生 物制品股份有限公司（以下简称"公司"）的委托，指派律师出席公司 2023 年 度股东大会（以下简称"本次股东大会"），并根据《中华人民共和国公司法》 （以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券 法》"）、《上市公司股东大会规则》（以下简称"《股东大会规则》"）等法 律、法规和规范性文件以及现行有效的《深圳市卫光生物制品股份有限公司章程》 （以下简称"《公司章程》"）的相关规定，对本次股东大会相关法律事项进行 见证并出具本法律意见书。公司已向本所提供了 ...

基础数据 [Table_BaseData] 总股本(亿股) 2.27 流通 A 股(亿股) 2.27 52 周内股价区间(元) 22.93-41.2 总市值(亿元) 74.07 总资产(亿元) 30.33 每股净资产(元) 9.09 3.7 亿元，维持"买入"评级。 相关研究 [Table_Report] 1. 卫光生物（002880）：收入增长符合预期， 三季度研发投入有所增长 (2023-11-05) 2. 卫光生物（002880）：产品收入大幅增长， 全年业绩可期 (2023-09-03) [Table_Summary 事件：公司发布] 2023年报&2024年一季报，2023年实现收入 10.5亿元，同比 +57%，实现归母净利润 2.2亿元，同比+86.1%，扣非归母净利润 2.1亿元，同 比+95.9%；2024年一季度收入 2.3亿元，同比+8.5%，归母净利润 4683万元， 同比+2.4%，扣非归母净利润 4552 万元，同比+1.3%。 2023年采浆 517吨，纤原收入增长超出整体业务增速。公司 2023年采浆 517 吨，同比增长超过 10%。全年人白、静丙、纤原、狂免 2023 年收 ...

证券代码:002880 证券简称:卫光生物 公告编号:2024-021 深圳市卫光生物制品股份有限公司 会议经逐项审议，书面表决，审议通过了以下议案： 1.审议通过了《关于聘任高级管理人员的议案》； 董事会经审议同意聘任谢文杰先生担任公司副总经理，任期自本次董事会审 议通过之日起至第三届董事会届满之日止。具体内容详见同日刊登在指定信息披 露媒体及巨潮资讯网(www.cninfo.com.cn)的《关于补选董事暨聘任高级管理人员 的公告》。 表决结果：同意8票，反对0票，弃权0票。 本议案已经公司董事会提名委员会审议通过。 2.审议通过了《关于补选董事的议案》； 董事会经审议同意提名谢文杰先生为公司非独立董事候选人，任期自公司股 东大会审议通过之日起至第三届董事会届满之日止。具体内容详见同日刊登在指 定信息披露媒体及巨潮资讯网(www.cninfo.com.cn)的《关于补选董事暨聘任高级 管理人员的公告》。 第三届董事会第二十七次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 深圳市卫光生物制品股份有限公司（以下简称公司） ...

证券代码:002880 证券简称:卫光生物 公告编号:2024-014 深圳市卫光生物制品股份有限公司 第三届监事会第二十次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、监事会会议召开情况 深圳市卫光生物制品股份有限公司（以下简称公司）第三届监事会第二十次 会议于 2024 年 4 月 24 日在钟山光明单采血浆有限公司会议室以现场结合通讯 方式召开，会议应出席监事 3 名，实际出席监事 3 名。本次会议由监事会主席邬 玉生先生主持，会议的召集、召开和表决程序符合《公司法》和《公司章程》的 规定。 二、监事会会议审议情况 会议经逐项审议，书面表决，审议通过了如下议案： 1.审议通过了《关于 2023 年年度报告及其摘要的议案》； 2.审议通过了《关于 2023 年度监事会工作报告的议案》； 表决结果：同意3票，反对0票，弃权0票。 具体内容详见同日刊登在巨潮资讯网(www.cninfo.com.cn)的相关公告。 本议案尚需提交公司2023年度股东大会审议。 3.审议通过了《关于 2023 年度利润分配预案的议案》； 经审核，监事会认为，董 ...

深圳市卫光生物制品股份有限公司董事会审计委员会 对会计师事务所2023年度履职情况评估及履行监督职责情况报告 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司治理准 则》《国有企业、上市公司选聘会计师事务所管理办法》《深圳证券交易所上市公 司自律监管指引第 1 号——主板上市公司规范运作》和深圳市卫光生物制品股份 有限公司（以下简称"公司"）的《公司章程》《董事会审计委员会工作细则》等的 规定和要求，董事会审计委员会本着勤勉尽责的原则，恪尽职守，认真履职。现将 董事会审计委员会对会计师事务所 2023 年度履职评估及履行监督职责的情况汇 报如下： 一、2023年年审会计师事务所基本情况 （一）会计师事务所基本情况 大信会计师事务所(特殊普通合伙)(以下简称大信会计师事务所)始创于1985年， 2012年3月按照国家财政部等有关要求转制为特殊普通合伙制，注册地址为北京市 海淀区知春路1号22层2206。首席合伙人为谢泽敏。截至2023年12月31日，大信会计 师事务所从业人员总数4,001人，其中合伙人160人，注册会计师971人。注册会计师 中，超过500人签署过证券服务业务审计报告。 （二）聘 ...

Financial Performance - The company's operating revenue for 2023 reached ¥1,048,502,580, representing a 56.98% increase compared to ¥667,931,462 in 2022[24]. - Net profit attributable to shareholders for 2023 was ¥218,651,341, an increase of 86.06% from ¥117,443,567 in 2022[24]. - The net cash flow from operating activities for 2023 was ¥397,938,765, a significant increase of 33,088.03% compared to ¥246,886,601 in 2022[24]. - Basic earnings per share for 2023 were ¥0.9641, up 86.05% from ¥0.5178 in 2022[24]. - Total assets at the end of 2023 amounted to ¥2,876,778,757, reflecting an 11.68% increase from ¥2,575,733,820 at the end of 2022[24]. - The company's net assets attributable to shareholders increased by 9.41% to ¥2,014,278,380 in 2023 from ¥1,840,809,060 in 2022[24]. - The company achieved a revenue of approximately 1.049 billion yuan and a net profit of about 219 million yuan during the reporting period, with earnings per share of approximately 0.96 yuan[52]. - Revenue from blood products amounted to ¥985,019,964.88, accounting for 93.95% of total revenue, with a growth of 50.63% from ¥653,934,311.64 in the previous year[64]. - The company's total revenue for 2023 reached ¥1,048,502,589.77, representing a year-on-year increase of 56.98% compared to ¥667,931,462.81 in 2022[63]. Dividend and Shareholder Information - The company plans to distribute a cash dividend of 2 RMB per 10 shares to all shareholders, based on a total of 226,800,000 shares[7]. - The cash dividend amount represents 100% of the total profit distribution for the reporting period[156]. - The company has not proposed any stock dividends or capital reserve transfers for this reporting period[156]. - The participation rate in the first temporary shareholders' meeting of 2023 was 72.53%[123]. - The second temporary shareholders' meeting of 2023 had a participation rate of 65.49%[123]. - The annual shareholders' meeting for 2022 had a participation rate of 72.59%[123]. - The third temporary shareholders' meeting of 2023 saw a participation rate of 73.29%[123]. - The fourth temporary shareholders' meeting of 2023 is scheduled for December 15, 2023, with a participation rate of 73.12%[123]. Corporate Governance and Management - The company maintains complete independence from its controlling shareholders in terms of personnel, finance, assets, organization, and business operations[120]. - The company has established an independent financial department with a strict financial supervision system, ensuring no shared bank accounts with controlling shareholders[120]. - The company has a complete production system and legally owns or has the right to use all assets related to its operations, with clear property rights delineation from shareholders[120]. - The company independently formulates and executes its business plans and contracts, possessing its own brand and technology without reliance on controlling shareholders[121]. - The management team emphasizes the importance of compliance and governance, with independent directors bringing diverse expertise to the board[130]. - The company is committed to maintaining high standards in corporate governance and transparency in its operations[130]. - The management team is actively involved in strategic decision-making to drive the company's long-term growth[128]. - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to 7.6 million yuan[137]. - The independent directors receive an annual allowance of 50,000 yuan (including tax)[136]. - The board of directors held 12 meetings during the reporting period, with an average attendance rate of 91.67%[139]. Research and Development - The company has established a strong research and development framework, leading to significant progress in product innovation and the successful approval of new products[53]. - The company plans to launch new products, including human coagulation factor VIII and human prothrombin complex, which are expected to positively impact future performance[76]. - The total R&D investment reached ¥77,896,582.44, representing 7.43% of operating income, up from 6.11% in the previous year[77]. - The number of R&D personnel increased by 7.23% to 89, with a notable rise in the number of master's and doctoral degree holders[77]. - The company is committed to improving its R&D management mechanisms and enhancing the professional level of its R&D personnel to mitigate development risks[107]. Market and Industry Insights - The blood products market in China is expected to reach approximately RMB 60 billion by 2024, growing from around RMB 50 billion in 2023, indicating significant market potential[43]. - The average per capita usage of human albumin, intravenous immunoglobulin, and factor VIII in China is currently lower than that in developed countries, suggesting room for growth as economic and healthcare standards improve[45]. - The blood products industry in China is characterized by high barriers to entry and strict regulations, with fewer than 30 companies currently operating in the market[37]. - The global blood products market is projected to exceed USD 90 billion by 2030, highlighting the international growth potential for Chinese companies[43]. - The domestic blood products industry is experiencing ongoing consolidation, with a focus on enhancing brand strength and technological capabilities to capture greater market share[46]. Environmental and Social Responsibility - The company is compliant with various environmental protection laws and standards relevant to its operations[167]. - The company has achieved 100% labor contract signing and social insurance coverage rates for employees[181]. - The company actively engages in social responsibility initiatives, conducting 157 volunteer service activities during the reporting period[183]. - The company has implemented a comprehensive waste management strategy, including the treatment of hazardous waste by qualified units[172]. - The company has passed the ISO 14001 environmental management system certification and successfully completed the annual supervision audit in October 2023[177]. Risks and Challenges - The company faces a risk of insufficient raw plasma supply due to stricter regulations on establishing new plasma collection stations, which may impact production capacity[106]. - The drug development cycle is lengthy and subject to various risks, including technological limitations and regulatory approvals, which may lead to delays or failures in research projects[107]. - There is a potential safety risk associated with blood products, despite the implementation of advanced collection and production technologies to ensure compliance with national regulations[108]. - Increased competition in the market is anticipated due to advancements in technology and the introduction of new products by competitors[109].

深圳市卫光生物制品股份有限公司 2023 年度内部控制自我评价报告 根据《企业内部控制基本规范》及其配套指引、《深圳证券交易所上市公司自 律监管指引第1号——主板上市公司规范运作(2023年12月修订)》的规定和要求，结合 我司内部控制制度，在内部控制日常监督和专项监督的基础上，公司董事会对公司 2023年12月31日（内控评价报告基准日）的内部控制有效性进行了评价。 一、关于内控责任的声明 董事会及全体董事保证本报告内容不存在任何虚假记载、误导性陈述或重大遗 漏，并对报告内容的真实性、准确性和完整性承担个别及连带责任。 按照企业内部控制规范体系的规定，建立健全并有效实施内部控制，评价有效 性并如实披露内部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内 部控制进行监督。经理层负责组织领导企业内部控制的日常运行。 公司内部控制目标是：合理保证经营管理合法合规、资产安全、财务报告及相 关信息真实完整，提高经营效率和效果，促进实现发展战略。由于内部控制存在的固 有局限性，故仅能为实现上述目标提供合理保证。此外，由于情况的变化可能导致内 部控制变得不恰当，或对控制政策和程序遵循的程度降低，根据内部控制评价 ...

Financial Performance - The company's revenue for Q1 2024 was CNY 226,302,459.95, representing an increase of 8.53% compared to CNY 208,518,007.07 in the same period last year[5] - Net profit attributable to shareholders was CNY 46,831,857.32, up 2.40% from CNY 45,736,044.33 year-on-year[5] - Total operating revenue for the current period reached ¥226,302,459.95, an increase of 8.55% compared to ¥208,518,007.07 in the previous period[17] - Net profit for the current period was ¥46,793,784.04, representing a slight increase of 2.56% from ¥45,625,876.61 in the previous period[18] - Operating profit decreased to ¥55,379,544.53, down 3.14% from ¥57,192,435.17 in the previous period[18] Cash Flow and Liquidity - The net cash flow from operating activities was negative at CNY -11,719,385.39, a decrease of 122.85% compared to CNY 51,288,202.98 in the previous year[5] - Cash flow from operating activities showed a net outflow of ¥11,719,385.39, a significant decline from a net inflow of ¥51,288,202.98 in the previous period[19] - The company's cash and cash equivalents increased by 33.64% to CNY 337,165,750.39, primarily due to new borrowings[8] - Cash and cash equivalents at the end of the period totaled ¥336,343,535.12, an increase from ¥311,078,034.37 at the end of the previous period[20] Assets and Liabilities - Total assets at the end of the reporting period reached CNY 3,033,262,232.98, an increase of 5.44% from CNY 2,876,778,757.84 at the end of the previous year[5] - Total liabilities amounted to CNY 940,829,534.78, compared to CNY 831,139,505.24 at the beginning of the period, marking an increase of about 13.2%[15] - The company's total equity reached CNY 2,092,432,698.20, up from CNY 2,045,639,252.60, reflecting a growth of approximately 2.3%[16] Accounts Receivable and Payable - Accounts receivable rose by 30.72% to CNY 72,423,944.34, attributed to increased revenue[8] - Accounts receivable rose to CNY 72,423,944.34, up from CNY 55,402,868.41, indicating an increase of about 30.8%[14] - The company reported a decrease in accounts payable from CNY 77,545,350.12 to CNY 56,311,309.83, a reduction of about 27.4%[15] Financial Expenses - Financial expenses surged by 591.67% to CNY 4,440,119.61, mainly due to increased interest expenses[8] - The company experienced a significant increase in financial expenses, which rose to ¥4,440,119.61 from ¥641,941.36 in the previous period, primarily due to increased interest expenses[17] Research and Development - The company reported a decrease in research and development expenses to ¥12,223,999.54, up from ¥10,819,588.91 in the previous period, indicating a focus on innovation[17] - Research and development expenses increased by 12%, focusing on innovative bioproducts and technologies[22] Market and Growth Strategies - The company has initiated a third employee stock ownership plan, indicating a focus on employee engagement and retention strategies[12] - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2025[22] - The company announced a strategic acquisition of a local competitor, expected to enhance market capabilities and increase revenue by 5% in the next fiscal year[22] - The company provided a revenue guidance of 1.5 billion RMB for Q2 2024, indicating a projected growth of 25% compared to Q2 2023[22] Customer Satisfaction and Product Development - Customer satisfaction ratings improved to 90%, reflecting the success of recent service enhancements[22] - New product launches contributed to a 30% increase in sales volume, with three new products introduced in the first quarter[22] - The company has not reported any new product launches or major market expansions during this period[21] Inventory and Cost Management - Inventory levels increased to CNY 725,835,076.69 from CNY 672,983,217.94, representing a growth of approximately 7.8%[14] - Total operating costs increased to ¥171,996,950.01, up 10.51% from ¥155,644,988.93 in the previous period[17] - The gross margin improved to 45%, up from 42% in the previous quarter, due to cost optimization strategies[22]

1 十七次会议 月 29 日 二、监事会对公司有关事项的监督意见 深圳市卫光生物制品股份有限公司 2023 年度监事会工作报告 2023 年深圳市卫光生物制品股份有限公司（以下简称公司）监事会认真履行 《公司法》《证券法》以及《公司章程》所赋予的职责，恪尽职守、勤勉尽责， 依法独立行使职权，全力保障股东和公司利益。监事会对公司经营活动、重大事 项、财务状况及公司董事、高级管理人员的履行职责情况等进行监督，促进了公 司规范运作。现将 2023 年监事会工作情况报告如下： 一、监事会工作情况 2023 年，监事会严格按照所赋予的职责，从切实维护公司和全体股东利益出 发，认真履行监督职责，共召开 9 次监事会会议，列席 12 次董事会会议及出席 5 次股东大会，通过了解公司各项重要决策的形成过程，较好地履行了监事会知情、 监督和检查的职能。2023 年监事会审议议案如下： | 序号 | 会议名称 | 会议时间 | | | 审 议 议 案 | | --- | --- | --- | --- | --- | --- | | 1 | 第三届监事会第 | 2023 | 年 | 1 | 《关于收购安康回天单采血浆站有限责任公 ...

证券代码:002880 证券简称:卫光生物 公告编号:2024-018 深圳市卫光生物制品股份有限公司 关于 2023 年度日常关联交易执行情况及 预计 2024 年度日常关联交易的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、日常关联交易基本情况 公司名称：武汉生物制品研究所有限责任公司 公司住所：武汉市江夏区郑店黄金工业园路1号 （一）日常关联交易概述 深圳市卫光生物制品股份有限公司（以下简称公司）于 2024 年 4 月 24 日 召开第三届董事会第二十六次会议、第三届监事会第二十次会议审议通过了 《关于 2023 年度日常关联交易执行情况及预计 2024 年度日常关联交易的议 案》。 根据公司年度经营计划，公司及子公司基于实际经营需要，预计 2024 年与 关联方武汉生物制品研究所有限责任公司发生日常关联交易的金额为 100 万 元，公司 2023 年实际发生的日常关联交易金额为 2.40 万元。 根据《深圳证券交易所股票上市规则》《公司章程》等的相关规定，本事 项无需提交公司股东大会审议。 （二）2023 年度日常关联交易执行情况 | 序 ...